Navigation Links
Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System
Date:1/3/2008

WAYNE, Pa., Jan. 3 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq Capital Market: ESMC) today announced that its Sonomed, Inc. subsidiary received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the MASTER-VU(TM) ophthalmic B-scan ultrasound system. The MASTER-VU(TM) System consists of a B-scan probe that can be interfaced to a standard personal computer (via a USB cable connection) using Sonomed's proprietary software, thereby converting the personal computer into an ophthalmic ultrasound system. Sonomed plans to commence shipments of the product in the United States immediately.

Barry Durante, Sonomed's President stated: "The FDA clearance, along with the previously received CE certification, will allow Sonomed to market this new breakthrough instrumentation worldwide. With computers becoming standard in most ophthalmic physician offices, purchasing the probe and software offers complete portability for use in multiple locations. Loading the software in computers in multiple offices allows the physician to carry only the probe from office to office. We expect that the MASTER-VU(TM) will be a valuable addition to our product line in both the U.S. and international marketplace."

The MASTER-VU(TM) System adds to Escalon's wide range of top quality and market leading ultrasound systems. This flexible and easy-to-use instrument offers simple installation, low maintenance and immediate user productivity. The MASTER-VU features include:
-- Measurement calipers for multiple intraocular measurements.

-- Ability to save both 30-second "clips" as well as individual frames on

a scrolling frame manager.

-- On-screen annotation capability, including text and graphics.

-- Easy installation and low maintenance.

For additional information on the MASTER-VU(TM) System, please visit the Sonomed web site at http://www.sonomedinc.com or call customer service at 1-800-227- 1285.

Sonomed, Inc. is a diagnostic ultrasound company specializing in the design, manufacture and distribution of instruments for ophthalmology. Sonomed is focused on providing quality instrumentation for ophthalmic physicians' offices, clinics and hospitals.

Founded in 1987, Escalon develops markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products as well as vascular access devices. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. Escalon seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of Escalon's distribution capabilities, although any such partnerships or acquisitions may not occur. Escalon has headquarters in Wayne, Pennsylvania and manufacturing operations in Long Island, New York, New Berlin, Wisconsin, Dallas, Texas, Waterbury, Connecticut and Barrow-in-Furness, U.K.

Note: This press release contains statements that are considered forward- looking under the Private Securities Litigation Reform Act of 1995, including statements about Escalon's future prospects. They are based on Escalon's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to:
-- implement its growth and marketing strategies, improve upon the

operations of Escalon's business units, including the integration of

Drew's and MRP's operations, the reorganization of the Drew business

and the integration of any acquisitions Escalon may undertake, if any,

of which there can be no assurance,

-- implement cost reductions,

-- generate cash,

-- identify, finance and enter into business relationships and

acquisitions.

Other factors include uncertainties and risks related to:

-- new product development, commercialization, manufacturing and market

acceptance of new products,

-- marketing acceptance of existing products in new markets,

-- research and development activities, including failure to demonstrate

-- clinical efficacy,

-- delays by regulatory authorities, scientific and technical advances by

Escalon or third parties,

-- introduction of competitive products,

-- third party reimbursement and physician training, and

-- general economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Escalon's report on Form 10- K, and its other filings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.


'/>"/>
SOURCE Escalon Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Escalon(R) Announces Promotion of Industry Veteran Barry Durante to President of Sonomed, Inc.
2. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
3. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
4. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
5. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Perrigo Announces FDA Approval for Over-The-Counter Cetirizine Hydrochloride Tablets
8. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
9. Imaging Diagnostic Systems CEO Announces Retirement
10. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
11. NeurogesX, Inc. Announces $25 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... and London UK (PRWEB) , ... August 10, 2017 , ... ... will host a new educational webinar to demonstrate how Good Clinical Practice ... contracts, and site documents. In addition the webinar will discuss the importance of GCP ...
(Date:8/10/2017)... FL (PRWEB) , ... August 10, 2017 , ... ... that the stock market news outlet had initiated coverage on Next Group Holdings, ... growing and underserved consumer markets geared toward those that cannot engage in traditional ...
(Date:8/10/2017)... 10, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife" or the "Company"), today reported operational highlights and ... June 30, 2017. Revenue from biopreservation media ... in the second quarter of 2017, an increase of ...
(Date:8/8/2017)... ... August 08, 2017 , ... This webinar, ... Virtual Event, will discuss Phase Analysis Light Scattering (PALS) and Raman spectroscopy methods ... used to assess vaccine product quality and consistency regarding particle size, zeta potential ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
(Date:3/20/2017)... 2017 At this year,s CeBIT Chancellor Dr. ... DERMALOG. The Chancellor came to the DERMALOG stand together with the Japanese ... CeBIT partner country. At the largest German biometrics company the two government ... and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):